Loading...
Loading...
Celgene International Sàrl, a wholly owned subsidiary of Celgene
Corporation
CELG today announced that that the European
Medicines Agency's (EMA) Committee for Medicinal Products for Human Use
(CHMP) has adopted a positive opinion for an expanded indication of
VIDAZA® (azacitidine for injection) for the treatment of
adult patients aged 65 years or older with acute myeloid leukaemia (AML)
who are not eligible for haematopoietic stem cell transplantation
(HSCT). The expanded indication now covers patients who have >30%
myeloblasts according to the WHO classification; previously, the
indication covered AML patients with <30% blasts.
Myeloblasts are white cells in the bone marrow; in AML, their
functioning is disrupted and results in numerous non-functioning white
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in